+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Epigenetics in Precision Medicine. Translational Epigenetics Volume 30

  • Book
  • November 2021
  • Elsevier Science and Technology
  • ID: 5342362

In recent years, knowledge of epigenetic mechanisms underlying disease onset and progression has proven crucial for the development of novel early diagnosis and prognosis biomarkers for patient stratification and precision medicine. Epigenetics in Precision Medicine, a new volume in the Translational Epigenetics series, provides a thorough discussion and overview of current developments in clinical epigenetics with special emphasis on epigenetic biomarkers that can be used for clinical diagnosis, prognosis, patient stratification, and treatment monitoring. Disease types discussed include cancer, metabolic disorders, neurodegenerative diseases, bone disease, and immune-related disorders. The book examines the challenges of advancing epigenetics research and translating findings to the clinic and drug discovery in each of these areas, as well as current solutions; chapter authors discuss how to leverage epigenomic technologies, applications, and tools, such as next-generation sequencing, to discover new epigenetic biomarkers in disease and drug studies.

Epigenetics in Precision Medicine focuses on complex epigenetic mechanisms in several pathologies, and explores how epigenetics can power the advance of precision medicine, not only by improving in vitro diagnostic and prognostic tools, but by providing new therapeutic approaches to treat human disease.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

1. Perspectives and future directions of Translational Epigenetics in Personalized and Precision Medicine 2. Translational Epigenetics in Precision medicine of colorectal cancer 3. Epigenetics inPrecision medicine of breast cancer 4. Epigenetics and Precision medicine in prostate cancer 5. Epigenetics and precision medicine in lung cancer 6. Epigenetics and precision medicine in bone and Soft Tissue sarcomas 7. Epigenetics and precision medicine in gynecological cancer 8. Epigenetics in precision medicine of pancreatic cancer 9. Epigenetics and precision medicine in diabetes and obesity prevention and management 10. Epigenetics in precision medicine of cardiovascular disease 11. Epigenetic markers for major psychosis as targets for precision medicine 12. Epigenetics and precision medicine in infertility and reproductive medicine 13. Epigenetics and precision medicine in neurodegenerative Diseases 14. Epigenetics and precision medicine in auto-immune diseases 15. Epigenetics and precision medicine in allergic diseases 16. Epigenetics in spine curvature disorders 17. Epigenetics and precision medicine in infectious diseases 18. Epigenetics and precision medicine in Rare Diseases 19. EpiSwitch biomarkers based on chromosomal conformation signatures for personalized medicine 20. Application of hypermethylated DNA markers for the detection of circulating tumor DNA (ctDNA) in colorectal


Jose Luis Garcia-Gimenez CIBER Enfermedades Raras, Centre for Biomedical Research on Rare Diseases, University of Valencia, Spain. Dr. Garcia-Gimenez is a Senior Researcher at the Consortium Center for Biomedical Network Research, the Spanish Institute of Health Carlos III (ISCIII), and the INCLIVA Biomedical Research Institute, in the Dept. of Physiology at the Medicine and Dentistry School at the University of Valencia, Spain. Dr. García-Giménez is founder and CEO of EpiDisease S.L. (Spin-Off of CIBER-ISCIII), which develops the technology based on the patent EP15382319.0, currently in national phases (USTPO, EPO, CIPO and SIPO). EpiDisease received NEOTEC funds from CDTI and the Seal of Excellence from the European Commission in the SME Instrument Phase II H2020. Dr. García-Giménez has received 7 scientific and entrepreneurship national and international awards, including the National Award for Young Entrepreneurs in 2013 (awarded by the Spanish Ministry of Health) and the European Young Researcher from the Free Radical Research Society in 2009 and more recently the Eureka Innovation and Entrepreneurship Award in Melbourne (Australia). Dr. Garcia-Gimenez is a researcher at the University of Valencia. He is early in his career, but has been noticed as an up-and-coming authority in epigenetic biomarker research as it relates to disease, stress, and exercise.